DAK-Gesundheit
Germany · 645 open tenders · 4,749 documented awards
Current tenders
Software for Hospital Invoice Verification
Deadline 12 Oct ·
Software for Hospital Invoice Auditing
Deadline 12 Oct ·
Nationwide supply and assembly of furnishings for "Get2Gether rooms" in DAK-Gesundheit service locations
Deadline 19 Oct ·
Event logistics nationwide
Deadline 19 Oct ·
Event logistics nationwide
Deadline 19 Oct ·
Nationwide supply and installation of furnishings for "Get2Gether rooms" in the DAK-Gesundheit service centers
Deadline 19 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 26 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 29 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 29 Oct ·
Lecture and seminar for executives and staff representatives, lecture and seminar for employees
Deadline 30 Oct ·
BGM substance abuse prevention
Deadline 30 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active substance Apremilast, (OBO) ATC L04AA32 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient Ginkgo biloba leaf dry extract, (OBG) ATC N06DP01 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient sevelamer hydrochloride, (OBG) ATC V03AE02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Rotigotine, (OBG) ATC N04BC09 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Clindamycin + Benzoylperoxid, (OBG) ATC D10AF54 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient allergen extract from tree pollen (excl. in the form of pump solution), ATC V01AA05 for the period 01.01.25 - 31.12.26
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient teriflunomide, ATC L04AK02 for the period 01.10.2025 - 31.12.2025 (plus extension option 1x12 months)
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient sevelamer hydrochloride, (OBG) ATC V03AE02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a Para. 8 SGB V for the active substance allergen extract from tree pollen (excl. in the form of pump solution), ATC V01AA05 for the period 01.01.25 - 31.12.26
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient dexamethasone (excluding implant), (OBG) ATC S01BA01 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Clindamycin + Benzoylperoxide, (OBG) ATC D10AF54 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient Pyridostigmine (excluding extended-release Dafo.), (OBG) ATC N07AA02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Rotigotine, (OBG) ATC N04BC09 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient perindopril and indapamide (excluding perindopril as arginine salt), ATC C09BA54 for the period 01.02.25 - 31.01.27
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a Abs. 8 SGB V for the active ingredient Aripiprazole (excl. Dafo for the manufacture of a DIS), (OBO) ATC N05AX12 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient flupentixol, (OBG) ATC N05AF01 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a Abs. 8 SGB V for the active ingredient PEG-Epoetin beta, (OBO) ATC B03XA03 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient Baricitinib, (OBO) ATC L04AA37 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Lipegfilgrastim, (OBO) ATC L03AA14 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018197
2019242
2020202
2021244
2022266
2023372
2024891
20251,337
2026789
Clement What the numbers say about this buyer
- The median procedure drew 9 bids (3,316 procedures with a bid count); 7% ended with a single bidder. Country: median 3.1 bids.n = 3,316
- 81% of this buyer's awards went to companies that had already won here before (3,321 awards since 2017, spread over 567 companies). That is well above the national norm (45%) — newcomers have a harder time here than elsewhere.n = 3,321 awards since 2017
- The award came in at a median 79% of the estimated value (6 awards with both estimate and value) — pricing at the estimate is usually too high here. Country: 86%.n = 6
- Across 261 procedures with structured selection criteria, this buyer most often required: Staff qualifications (253 of 261), Professional liability insurance (11 of 261), References: services (6 of 261), Minimum annual turnover (5 of 261).n = 261
- From notice to award takes a median 47 days here (599 procedures). Country: 91 days.n = 599
- 83% of the bids received came from small and medium-sized enterprises (15 procedures with a bid mix). Country: 75%.n = 15
- 2% of awards went to companies from abroad (3,321 awards with a known winner country). National average: 1%.n = 3,321
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Expected next awards
From the rhythm of past awards per sector — an expectation, not an announcement. Hit rate so far: 26% of 11,200 closed expectation windows produced a notice.
- Oct 2026Health & social work
about every 4 months · 36 awards · last Jun 2026 to Motio Verbund GmbH - Oct 2026IT services
about every 4 months · 131 awards · last Jul 2026 to IMAGO - Oct 2026Business services
about every 2 months · 109 awards · last Sept 2026 to PIA Media GmbH - May 2027Post & telecom services
about every 13 months · 10 awards · last Apr 2026 to Deutsche Post InHaus Services - May 2027Education & training
about every 10 months · 4 awards · last Aug 2026 to TripleShift GmbH - Jun 2028Financial & insurance services
about every 30 months · 7 awards · last Dec 2025 to Ampega Investment GmbH
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 188 | 2022–2026 |
| kohlpharma GmbH · Merzig | 172 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 137 | 2022–2026 |
| CC Pharma GmbH · Densborn | 133 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 125 | 2015–2026 |
| axicorp Pharma B.V. · EC Den Haag | 92 | 2022–2025 |
| Originalis B.V. · Amsterdam | 83 | 2022–2025 |
| ratiopharm GmbH | 80 | 2015–2026 |
| Zentiva Pharma GmbH · Frankfurt am Main | 59 | 2015–2026 |
| Hexal AG · Holzkirchen | 58 | 2013–2025 |
From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.